Allogeneic stem cell transplantation for systemic mastocytosis – pro
Ustun et al and others have found that alloHCT can confer long-term OS in patients with advanced systemic mastocytosis (SM). HSCT should
be considered for those who are young and fit and have a suitable transplant donor. The outcome of transplanted patients (overall survival
and progression-free survival) appears to be favorable in nontransformed patients.
Ustun C, Gotlib J, Popat U, et al. Consensus opinion on allogeneic hematopoietic cell transplantation in advanced systemic mastocytosis. Biol Blood Marrow Transplant. 2016;22(8):1348-1356.
Ustun C, Reiter A, Scott BL, et al. Hematopoietic stem-cell transplantation for advanced systemic mastocytosis. J Clin Oncol. 2014;32(29):3264-74.
Peter Valent, Wolfgang R. Sperr, and Cem Akin, How I treat patients with advanced systemic mastocytosis (Blood. 2010;116(26):5812-5817)